Are peptides legal? What U.S. law and the FDA actually say

The law looks at the exact product and its supply route.

A peptide is a chain of amino acids. Amino acids are the small building blocks that also make proteins. That one word covers approved medicines, pharmacy preparations, and powders sold online. United States law does not treat those three things alike.

The exact product and supply route are starting checks for the federal records covered here. State rules and the details of a transaction can also matter. Three checks follow: whether the exact product is approved, whether compounding conditions apply, and whether a prescription stands behind it. Each answer sits in a different public record.

The sections below cover the federal layers and link the dated FDA pages behind each one. They do not explain how to get any substance. They give no amounts, preparation steps, product picks, or seller information.

This page is general education. It is not legal advice, and no lawyer reviewed it. It was not independently medically reviewed either. For your own situation, ask a licensed attorney or a clinician.

Four questions that people mix together.

The one word peptide often carries four separate questions. Each question has its own decision-maker and its own public document.

• Approval. Has FDA approved this exact product for a stated use? The record is Drugs@FDA, the agency's public database of approved products.
• Compounding eligibility. May a pharmacy or outsourcing facility compound a drug product containing this substance under the applicable federal conditions? The record is the FDA bulk drug substances lists.
• Lawful possession and sale. Does a federal law restrict this substance directly? Human growth hormone has its own criminal statute.
• Sport eligibility. May an athlete under anti-doping rules use it? The record is the World Anti-Doping Agency Prohibited List.

FDA approval applies to one named product and use.

Several peptide medicines carry FDA approval. Each approval covers one exact product. It names the dosage form, how the product enters the body (route), and the stated uses. Approval does not extend to every product that shares an ingredient name.

You can check an approval in Drugs@FDA. Search the brand name and the active ingredient. Then match the application number, the applicant, the dosage form, and the approved uses. This confirms FDA approval for that product. It does not decide whether a particular prescription, sale, or transaction meets every federal and state rule.

The directory of FDA-approved peptide products, linked under Read next, lists approvals product by product. Use it to check the exact FDA record, not as a general legal answer.

Compounded peptides use a narrow route with hard limits.

FDA describes 503A and 503B as separate federal pathways. Section 503A generally covers prescription compounding for an identified individual. Section 503B covers registered outsourcing facilities. Their conditions and exemptions differ.

A 503A compounder may use a bulk substance in a United States Pharmacopeia or National Formulary monograph, a component of an FDA-approved drug, or a substance on FDA's 503A bulks list when the required conditions are met. A 503B facility may use a 503B-listed bulk substance or a drug on FDA's shortage list, subject to its own conditions.

FDA states that compounded drugs are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before marketing. A shared ingredient name does not prove the same strength, sterility, stability, or evidence.

What FDA Category 2 means, and which peptides are in it.

FDA runs two interim policies for nominated bulk drug substances. One covers pharmacies under section 503A. The other covers outsourcing facilities under section 503B. Each policy sorts nominations into its own Category 1, Category 2, and Category 3.

Category 1 substances came with enough supporting information for FDA to evaluate. They may be eligible for the bulks list. FDA does not intend to take action against a compounder who uses one, under stated conditions.

Category 3 substances came with insufficient supporting information. They are not eligible for that policy, and FDA says it would consider taking action.

For Category 2, FDA says it has identified significant safety risks relating to the use of these substances in compounding pending further evaluation. For that reason, FDA does not intend to adopt the Category 1 policy for them. It says it would consider taking action against a compounder. Category 2 remains part of the interim policy.

FDA keeps one page for bulk drug substances that may present significant safety risks. FDA marks that page content current as of April 22, 2026. Several peptides appear in Category 2 on that page.

A Category 2 listing is separate from a place on a bulks list. For each entry, the page names the policy and gives the safety concern.

• Ipamorelin acetate, in Category 2 under the 503B policy, for certain routes of administration. FDA describes a risk for immunogenicity from aggregation or peptide-related impurities. It also cites a study that reported serious adverse events, including death, with intravenous use.
• Kisspeptin-10, in Category 2 under the 503A policy, for certain routes of administration. FDA has no, or only limited, safety-related information for those routes. It says it lacks sufficient information to know whether the drug would cause harm.
• Growth hormone releasing peptide-2 (GHRP-2), in Category 2 under the 503B policy, for injectable and nasal routes of administration. FDA describes a risk for immunogenicity from aggregation and peptide-related impurities.
• Growth hormone releasing peptide-6 (GHRP-6), in Category 2 under the 503B policy. FDA describes a potential effect on cortisol and an increase in blood glucose.
• Ibutamoren mesylate, in Category 2 under both the 503A and the 503B policies. FDA cites a potential for congestive heart failure in certain patients. It notes a trial stopped early over that signal.

Nominations that were withdrawn, and what FDA said about them.

The same FDA page carries a separate list of withdrawn nominations. A withdrawn nomination means the nominator pulled the request, so FDA never finished evaluating the substance. Withdrawn status does not ban a substance or place it on a criminal schedule.

FDA still records what it found before each request was pulled. Every entry below except dihexa acetate carries one shared finding. FDA describes a risk for immunogenicity for certain routes of administration. It also notes peptide-related impurities or aggregation.

Immunogenicity means the body may react to a drug as foreign. Most entries add a further finding, shown below. The list records regulatory status and implies no supply route.

• BPC-157. FDA says it lacks sufficient information to know whether the drug would cause harm.
• CJC-1295. FDA cites limited clinical data. It also cites serious adverse events, including increased heart rate and a systemic vasodilatory reaction.
• AOD-9604. FDA calls the immunogenicity risk significant. It cites serious adverse events that may be associated. Causality is unclear.
• Epitalon. FDA has not identified safety-related information for the proposed routes of administration.
• Melanotan II. Published case reports discuss serious adverse events, including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism.
• Thymosin beta-4 fragment (TB-500). FDA identified no human exposure data.
• Selank acetate (TP-7). FDA lacks important information about any safety issues raised by this substance in humans.
• Semax (heptapeptide). FDA describes no, or limited, safety-related information for the proposed routes of administration.
• GHK-Cu, for injectable routes of administration. FDA describes limited data in humans to inform safety-related considerations.
• Cathelicidin LL-37. Nonclinical research findings suggest detrimental effects on male reproduction. They also suggest the drug can be protumorigenic in some tissues.
• MOTS-c. FDA calls the immunogenicity risk significant and identified no human exposure data.
• Dihexa acetate. FDA has not identified any human exposure data for this substance, for any route.
• Thymosin alpha-1. FDA calls the immunogenicity risk significant. It describes the available safety-related information as inadequate.

What a research-use-only label means under drug law.

Some products are sold with labels saying research use only. Some add not for human consumption. That wording does not establish FDA approval or a lawful route for human use.

FDA's page about unapproved GLP-1 drugs addresses this directly for one family of products. FDA marks that page content current as of September 1, 2026. On it, FDA says it warned companies that illegally sold unapproved drugs.

Those drugs were falsely labeled for research purposes or not for human consumption. They were sold to consumers for human use.

The same page describes warning letters to telehealth companies. Those firms marketed unapproved drugs such as retatrutide, including direct marketing to consumers. That record covers GLP-1 products.

Do not stretch the GLP-1 record to every peptide. FDA also publishes warning letters in a searchable database.

This page does not review sellers, vendors, or ways of buying products.

Human growth hormone has its own criminal law.

Federal criminal law, at 21 U.S.C. section 333(e), singles out one peptide hormone. It makes it a crime to knowingly distribute human growth hormone, or possess it with intent to distribute, for any use in humans. The narrow exception covers treatment of a disease or other recognized medical condition, where FDA has authorized that use and a physician orders it.

That authorization comes from the Secretary under section 355. A prescription alone does not bring a use inside the exception if FDA has not authorized that use. The statute sets prison terms of up to 5 years.

The term rises to 10 years where a person under 18 is involved. It defines human growth hormone as somatrem, somatropin, or an analogue of either.

FDA has approved somatropin products, such as Genotropin under BLA 020280. You can confirm them in Drugs@FDA. The carve-out in the statute depends on that approved and prescribed route.

The statute is specific to human growth hormone as it defines that term. It does not cover every peptide or act as a general peptide law. It shows how a federal rule can attach to one named substance.

Did a 2025 or 2026 change make peptides legal?

A popular claim says that peptides became legal again during 2025 or 2026. Several pages that rank for this question repeat it. Some of those pages are written by sellers who benefit if readers believe it.

The FDA bulk substances pages record one dated change. FDA guidance sets a cutoff: the agency does not intend to place bulk drug substances nominated on or after January 7, 2025 into these categories. The 503A page, marked content current as of May 14, 2026, carries that statement. The 503B page carries it too and is marked content current as of January 7, 2025.

The change affects how FDA handles new nominations from that date forward. It does not make any substance lawful, approved, or safe. It does not remove anything already placed in Category 2.

The Category 2 peptides named above were still listed on the April 22, 2026 page. No FDA page reviewed here declares a class of peptides newly lawful. News coverage of a possible change does not alter the record.

State rules and practice rules also apply.

Federal law is only one layer. State pharmacy boards, medical boards, and state drug laws add their own rules. Those rules differ. A prescriber's scope of practice and a pharmacy's license terms are set at the state level.

No state-by-state table appears here. The only sources found for that detail were weak sites with no primary citation, and the claim could not be verified. A table built on those sources may be wrong.

A state pharmacy board or a licensed attorney can answer a state question. Treat a state chart found online as unverified until it traces to a state statute, rule, or board notice.

Sport and workplace rules are a separate system.

Anti-doping rules run separately from drug law. The World Anti-Doping Agency Prohibited List names substances and categories for athletes under the World Anti-Doping Code. It says whether a restriction applies at all times or only in competition. An approved medicine can still be prohibited in sport.

The Prohibited List itself is linked in the sources below. The comparison of peptides and steroids, under Read next, explains how the list works. Athletes should also check the rules of their own governing body. Workplace drug testing is a third system, run by employers.

Legal does not mean approved, proven, or safe.

A molecule becomes a formulation. A formulation given by a route makes a finished product. The product may or may not have an approved labeled use. Its legal status can depend on more than the FDA record.

The records on this page do not answer every question about a product, person, or transaction. Whether a peptide helps a person is a separate question, answered by studies in people of that exact product. Whether it is safe for one person is a question for a clinician.